pioglitazone has been researched along with Cancer of Colon in 11 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the chemopreventive effects of pioglitazone (exogenous PPAR gamma ligand) on rat colon aberrant crypt foci, a rat carcinogenesis model induced by dimethylhydrazine (DMH), and to compare pioglitazone with sulindac (a NSAID)." | 7.72 | [Pioglitazone, a peroxisome proliferators-activated receptor gamma ligand, inhibits dimethylhydrazine (DMH) induced aberrant crypt foci in rats]. ( Dong, X; Jin, Z; Li, J; Lv, Y, 2003) |
| "To investigate the chemopreventive effects of pioglitazone (exogenous PPAR gamma ligand) on rat colon aberrant crypt foci, a rat carcinogenesis model induced by dimethylhydrazine (DMH), and to compare pioglitazone with sulindac (a NSAID)." | 3.72 | [Pioglitazone, a peroxisome proliferators-activated receptor gamma ligand, inhibits dimethylhydrazine (DMH) induced aberrant crypt foci in rats]. ( Dong, X; Jin, Z; Li, J; Lv, Y, 2003) |
| "Considering the role of PPARγ in colorectal cancer (CRC) as a tumor suppressor, the GEO database was used to identify candidate genes that affect the activation of PPARγ protein in CRC cell lines." | 2.82 | Identification of a novel interplaying loop of PPARγ and respective lncRNAs are involved in colorectal cancer progress. ( Esmaeili, M; Ghaedi, K; Hajipour, M; Hasehmi, M; Hushmandi, K; Mahdevar, M; Mirzaei, S; Mokhtari, K; Nasr-Esfahani, MH; Peymani, M, 2022) |
| "Ischemia reperfusion injury (IRI) during liver-metastasis resection for treatment of colon cancer may increase the risk of further metastasis." | 1.56 | Ischemia reperfusion-induced metastasis is resistant to PPARγ agonist pioglitazone in a murine model of colon cancer. ( Aoki, T; Bouvet, M; Fukuda, Y; Higuchi, T; Hoffman, RM; Inubushi, S; Murakami, M; Nishino, H; Singh, SR; Sugisawa, N; Tashiro, Y; Yamamoto, J, 2020) |
| "∆2-pioglitazone treatment did not trigger cells to enter apoptosis but enhanced the autophagy process." | 1.40 | Evaluation of ∆2-pioglitazone, an analogue of pioglitazone, on colon cancer cell survival: Evidence of drug treatment association with autophagy and activation of the Nrf2/Keap1 pathway. ( Chaimbault, P; Huber, S; Schohn, H; Valente, S, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Hajipour, M | 1 |
| Mokhtari, K | 1 |
| Mahdevar, M | 1 |
| Esmaeili, M | 1 |
| Peymani, M | 1 |
| Nasr-Esfahani, MH | 1 |
| Mirzaei, S | 1 |
| Hasehmi, M | 1 |
| Hushmandi, K | 1 |
| Ghaedi, K | 1 |
| Tashiro, Y | 1 |
| Nishino, H | 1 |
| Higuchi, T | 1 |
| Sugisawa, N | 1 |
| Fukuda, Y | 1 |
| Yamamoto, J | 1 |
| Inubushi, S | 1 |
| Aoki, T | 1 |
| Murakami, M | 1 |
| Singh, SR | 1 |
| Bouvet, M | 1 |
| Hoffman, RM | 1 |
| Sinha, VR | 1 |
| Sethi, S | 1 |
| Huber, S | 1 |
| Valente, S | 1 |
| Chaimbault, P | 1 |
| Schohn, H | 2 |
| Papi, A | 1 |
| Rocchi, P | 1 |
| Ferreri, AM | 1 |
| Orlandi, M | 1 |
| Flores, MBS | 1 |
| Rocha, GZ | 1 |
| Damas-Souza, DM | 1 |
| Osório-Costa, F | 1 |
| Dias, MM | 1 |
| Ropelle, ER | 1 |
| Camargo, JA | 1 |
| de Carvalho, RB | 1 |
| Carvalho, HF | 1 |
| Saad, MJA | 1 |
| Carvalheira, JBC | 1 |
| Osawa, E | 1 |
| Nakajima, A | 2 |
| Wada, K | 2 |
| Ishimine, S | 1 |
| Fujisawa, N | 2 |
| Kawamori, T | 1 |
| Matsuhashi, N | 1 |
| Kadowaki, T | 2 |
| Ochiai, M | 1 |
| Sekihara, H | 1 |
| Nakagama, H | 2 |
| Li, J | 1 |
| Lv, Y | 1 |
| Dong, X | 1 |
| Jin, Z | 1 |
| Fiatte, C | 1 |
| Huin, C | 1 |
| Bertin, I | 1 |
| Lesuffleur, T | 1 |
| Pluvinet, A | 1 |
| Touche, N | 1 |
| Plénat, F | 1 |
| Dauça, M | 1 |
| Domenjoud, L | 1 |
| Choi, IK | 1 |
| Kim, YH | 1 |
| Kim, JS | 1 |
| Seo, JH | 1 |
| Fujisawa, T | 1 |
| Takahashi, H | 1 |
| Ikeda, I | 1 |
| Tomimoto, A | 1 |
| Yonemitsu, K | 1 |
| Nakajima, N | 1 |
| Kudo, C | 1 |
| Kubota, N | 1 |
| Terauchi, Y | 1 |
| Blumberg, RS | 1 |
1 review available for pioglitazone and Cancer of Colon
| Article | Year |
|---|---|
Identification of a novel interplaying loop of PPARγ and respective lncRNAs are involved in colorectal cancer progress.
Topics: Colonic Neoplasms; Colorectal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Ligands; Pi | 2022 |
10 other studies available for pioglitazone and Cancer of Colon
| Article | Year |
|---|---|
Ischemia reperfusion-induced metastasis is resistant to PPARγ agonist pioglitazone in a murine model of colon cancer.
Topics: Animals; Colonic Neoplasms; Cytokines; Disease Models, Animal; Disease Progression; Inflammation; Li | 2020 |
Pioglitazone hydrochloride: chemopreventive potential and development of site-specific drug delivery systems.
Topics: 1,2-Dimethylhydrazine; Animals; Anticarcinogenic Agents; Cell Proliferation; Colon; Colonic Neoplasm | 2015 |
Evaluation of ∆2-pioglitazone, an analogue of pioglitazone, on colon cancer cell survival: Evidence of drug treatment association with autophagy and activation of the Nrf2/Keap1 pathway.
Topics: Antineoplastic Agents; Autophagy; Cell Proliferation; Cell Survival; Colonic Neoplasms; HCT116 Cells | 2014 |
RXRgamma and PPARgamma ligands in combination to inhibit proliferation and invasiveness in colon cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Movement; Cell Proliferation; Cell S | 2010 |
RETRACTED: Obesity-induced increase in tumor necrosis factor-α leads to development of colon cancer in mice.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Azoxymethane; Blotting, Western; | 2012 |
Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice.
Topics: Animals; Antineoplastic Agents; Azoxymethane; Carcinogens; Chromans; Colon; Colonic Neoplasms; Femal | 2003 |
[Pioglitazone, a peroxisome proliferators-activated receptor gamma ligand, inhibits dimethylhydrazine (DMH) induced aberrant crypt foci in rats].
Topics: 1,2-Dimethylhydrazine; Aberrant Crypt Foci; Animals; Colonic Neoplasms; Female; Intestinal Mucosa; P | 2003 |
Genetic analysis of peroxisome proliferator-activated receptor gamma1 splice variants in human colorectal cell lines.
Topics: Base Sequence; Caco-2 Cells; Chromans; Chromosome Mapping; Colonic Neoplasms; Cycloheximide; Dactino | 2006 |
PPAR-gamma ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo.
Topics: Animals; beta Catenin; Cell Proliferation; Colonic Neoplasms; Disease Models, Animal; Dose-Response | 2008 |
Peroxisome proliferator-activated receptor gamma (PPARgamma) suppresses colonic epithelial cell turnover and colon carcinogenesis through inhibition of the beta-catenin/T cell factor (TCF) pathway.
Topics: Active Transport, Cell Nucleus; Animals; Azoxymethane; beta Catenin; Caco-2 Cells; Cell Proliferatio | 2008 |